| ［1］ Mehren MV, Keedy V, Paz IB, et al. NCCN Clinical Practice Guidelines in Oncology: Soft Tissue Sarcoma, Version 2.2017［EB/OL］. ［2017208］. http://www.nccn.org.
［2］ Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: Revised RECIST guideline (version1.1)［J］. Eur J Cancer, 2009, 45: 228247. DOI: 10.1016/j.ejca.2008.10.026.
［3］ Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017［J］. CA Cancer J Clin, 2017, 67(1): 730. DOI: 10.3322/caac.21387.
［4］ Langezaal SM, Graadt van Roggen JF, CletonJansen AM, et al. Malignant melanoma is genetically distinct from clear cell sarcoma of tendons and aponeurosis (malignant melanoma of soft parts)［J］. Br J Cancer, 2001, 84(4): 535538. DOI: 10.1054/bjoc.2000.1628.
［5］ Panagopoulos I, Mertens F, DebiecRychter M, et al. Molecular genetic characterization of the EWS/ATF1 fusion gene in clear cell sarcoma of tendons and aponeuroses［J］. Int J Cancer, 2002, 99(4): 560567. DOI: 10.1002/ijc.10404.
［6］ Antonescu CR, Nafa K, Segal NH, et al. EWSCREB1: a recurrent variant fusion in clear cell sarcomaassociation with gastrointestinal location and absence of melanocytic differentiation［J］. Clin Cancer Res, 2006, 12(18): 53565362. DOI: 10.1158/10780432.CCR052811.
［7］ Enzinger FM. Clearcell sarcoma of tendons and aponeuroses: an analysis of 21 cases［J］. Cancer, 1965, 18: 11631174.
［8］ Chung EB, Enzinger FM. Malignant melanoma of soft parts: a reassessment of clear cell sarcoma［J］. Am J Surg Pathol, 1983, 7(5): 405413.
［9］ Malchau SS, Hayden J, Hornicek F, et al. Clear cell sarcoma of soft tissue［J］. J Surg Oncol, 2007, 95(6): 519522. DOI: 10.1002/jso.20730.
［10］ Kawai A, Hosono A, Nakayama R, et al. Clear cell sarcoma of tendons and aponeuroses: a study of 75 patients［J］. Cancer, 2007, 109(1): 109116. DOI: 10.1002/cncr.22380.
［11］ Hisaoka M, Ishida T, Kuo TT, et al. Clear cell sarcoma of soft tissue: a clinicopathologic, immunohistochemical, and molecular analysis of 33 cases［J］. Am J Surg Pathol, 2008, 32(3): 452460. DOI: 10.1097/PAS.0b013e31814b18fb.
［12］ Kuiper DR, Hoekstra HJ, Veth RP, et al. The management of clear cell sarcoma［J］. Eur J Surg Oncol, 2003, 29(7): 568570.
［13］ 商冠宁, 孙平, 邢浩, 等. 透明细胞肉瘤的临床治疗与预后分析［J］. 中国骨肿瘤骨病, 2010, 9(5): 429432. DOI: 10.3969/j.issn.16711971.2010.05.014.
［14］ Lucas DR, Nascimento AG, Sim FH. Clear cell sarcoma of soft tissues: Mayo clinical experience with 35 cases［J］. Am J surg pathol, 1992, 16(12): 11971204.
［15］ Steger GG, Wrba F, Mader R, et al. Complete remission of metastasized clear cell sarcoma of tendons and aponeuroses［J］. Eur J Cancer, 1991, 27(3): 254256.
［16］ 邢汝维, 方志伟, 宋金纲, 等. 透明细胞肉瘤的治疗及疗效分析［J］. 中华骨科杂志, 2005, 25(8): 485490. DOI: 10.3760/j.issn:02532352.2005.08.009
［17］ Davis IJ, McFadden AW, Zhang Y, et al. Identification of the receptor tyrosine kinase cMet and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma［J］. Cancer Res, 2010, 70(2): 639645. DOI: 10.1158/00085472.CAN091121.
［18］ Uguen A, Marcorelles P, De Braekeleer M. Targeting BRAF mutants in clearcell sarcomas of soft tissue: beyond sarcoma or melanoma classification［J］. Invest New Drugs, 2016, 34(2): 253254. DOI: 10.1007/s1063701503192.
［19］ Stacchiotti S, Grosso F, Negri T, et al. Tumor response to sunitinib malate observed in clearcell sarcoma［J］. Ann Oncol, 2010, 21(5): 11301131. DOI: 10.1093/annonc/mdp611.
［20］ Paoluzzi L, Cacavio A, Ghesani M, et al. Response to antiPD1 therapy with nivolumab in metastatic sarcomas［J］. Clin Sarcoma Res, 2016, 6: 24. DOI: 10.1186/s1356901600640.
［21］ Mavrogenis A, Bianchi G, Stavropoulos N, et al. Clinicopathological features, diagnosis and treatment of clear cell sarcoma/melanoma of soft parts［J］. Hippokratia, 2013, 17(4): 298302.
［22］ Ben Hamida KS, Bouhaouala MH, Derbel F, et al. Clear cell sarcoma: a rare entity within melanoma［J］. Joint Bone Spine, 2009, 76(4): 430431. DOI: 10.1016/j.jbspin.2008.11.013.
［23］ Sara AS, Evans HL, Benjamin RS. Malignant melanoma of soft parts (clear cell sarcoma). A study of 17 cases, with emphasis on prognostic factors［J］. Cancer, 1990, 65(2): 367374.
［24］ Hocar O, Le Cesne A, Berissi S, et al. Clear cell sarcoma (malignant melanoma) of soft parts: a clinicopathologic study of 52 cases［J］. Dermatol Res Pract, 2012, 2012: 984096. DOI: 10.1155/2012/984096.
［25］ Bianchi G, Charoenlap C, Cocchi S, et al. Clear cell sarcoma of soft tissue: a retrospective review and analysis of 31 cases treated at Istituto Ortopedico Rizzoli［J］. Eur J Surg Oncol, 2014, 40(5): 505510. DOI: 10.1016/j.ejso.2014.01.016.
［26］ 高天, 刘佳勇, 樊征夫, 等. 软组织肉瘤化疗聚乙二醇化重组人粒细胞集落刺激因子预防中性粒细胞减少临床观察［J］. 中华肿瘤防治杂志, 2015, 22(16): 13131317. DOI: 10.16073/j.cnki.cjcpt.2015.16.015.
［27］ Cornillie J, van Cann T, Wozniak A, et al. Biology and management of clear cell sarcoma: state of the art and future perspectives［J］. Expert Rev Anticancer Ther, 2016, 16(8): 839845. DOI: 10.1080/14737140.2016.1197122.
［28］ 申学杰, 曹水. 转移性软组织肉瘤化疗联合重组人血管内皮抑素治疗的有效性和安全性观察［J］. 中华肿瘤防治杂志, 2016, 23(19): 13131317. DOI: 10.16073/j.cnki.cjcpt.2016.19.008.
|
